Moderate or severe OHSS · assisted reproduction technology cycles
1 finding from 1 review
Moderate or severe OHSS ‐ Poor‐responders (MPA 10 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol · assisted reproduction technology cycles
1 finding from 1 review
no estimate extracted
1 study · 1 participants
GRADE not reported
Moderate or severe OHSS ‐ Normoresponders ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
1 finding from 1 review
Moderate or severe OHSS · assisted reproduction technology cycles
It is very uncertain whether summary of findings table ‐ Progestagen changes moderate or severe OHSS compared with gnRH agonist (very low certainty).
1 finding from 1 review
Moderate or severe OHSS · assisted reproduction technology cycles
1 finding from 1 review
OHSS · Women undergoing ovarian stimulation with gonadotrophins in IVF and ICSI procedures
Monitoring ovarian stimulation by transvaginal ultrasound (TVUS) only showed no clear difference in OHSS rate (mild, moderate or severe) per woman compared with monitoring with TVUS plus serum estradiol (low certainty).
1 finding from 1 review
Moderate or severe OHSS · women undergoing assisted reproduction
Dopamine agonist probably leads to lower incidence of moderate or severe OHSS compared with placebo/no intervention (moderate certainty).
1 finding from 1 review
Moderate or severe OHSS · women undergoing assisted reproduction
It is very uncertain whether dopamine agonist changes incidence of moderate or severe OHSS compared with other active intervention (very low certainty).
1 finding from 1 review
Moderate or severe OHSS · women undergoing assisted reproduction
Dopamine agonist plus co‐intervention may leads to lower incidence of moderate or severe OHSS compared with co‐intervention (low certainty).
1 finding from 1 review
Intervention not reported
Moderate/severe OHSS · couples with unexplained infertility
The intervention showed no clear difference in moderate/severe OHSS (moderate certainty).
1 finding from 1 review
Venous thrombo‐embolism (DVT or PE): CEE 0.625 mg (moderate dose) · relatively healthy postmenopausal women
Oestrogen‐only hormone therapy (HT) showed no clear difference in venous thromboembolism (DVT or PE): CEE 0.625 mg (moderate dose) compared with placebo (moderate certainty).
1 finding from 1 review
Moderate or severe OHSS · women at high risk of OHSS
It is very uncertain whether human albumin changes moderate or severe OHSS compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Moderate or severe OHSS · women at high risk of OHSS
It is very uncertain whether HES changes moderate or severe OHSS compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Moderate or severe OHSS · women at high risk of OHSS
Mannitol may leads to lower moderate or severe OHSS compared with placebo / no treatment (low certainty).
1 finding from 1 review
Moderate or severe OHSS · patients with final oocyte maturation triggering in IVF and ICSI cycles
RhCG showed no clear difference in OHSS per woman ‐ moderate to severe OHSS compared with uhCG (low certainty).
1 finding from 1 review
Incidence of moderate OHSS · patients with final oocyte maturation triggering in IVF and ICSI cycles
It is very uncertain whether rhLH changes OHSS per woman ‐ Moderate OHSS compared with uhCG (very low certainty).
1 finding from 1 review
OHSS · subfertile women
GnRH agonist probably leads to lower OHSS (mild, moderate or severe): overall risk compared with HCG (moderate certainty).
1 finding from 1 review
Moderate or severe OHSS · subfertile women
GnRH agonist probably leads to lower OHSS (moderate or severe): overall risk compared with HCG (moderate certainty).
1 finding from 1 review
OHSS (mild, moderate or severe) in women at high risk of OHSS · subfertile women
GnRH agonist probably leads to lower OHSS (mild, moderate or severe) in women at high risk of OHSS compared with HCG (moderate certainty).
1 finding from 1 review
Intervention not reported
Moderate dose SSRI versus placebo Luteal or continuous administration · women with premenstrual syndrome
1 finding from 1 review